Table of Contents Author Guidelines Submit a Manuscript
Autoimmune Diseases
Volume 2012, Article ID 321614, 8 pages
Review Article

Evaluation of ENA-6 Profile by ELISA Immunoassay in Patients with Systemic Lupus Erythematodes

1Center for Genetics, Medical Faculty, University of Sarajevo, Cekalusa 90, Sarajevo, Bosnia and Herzegovina
2Department of Clinical immunology, KCUS, Sarajevo, Bosnia and Herzegovina
3Department of Biomedicine and Public Health, Faculty of Medicine, Osijek University, Osijek, Croatia

Received 27 April 2012; Accepted 8 August 2012

Academic Editor: Hiroshi Okamoto

Copyright © 2012 Izeta Aganovic-Musinovic et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Autoimmune diseases occur in 3−5% of the population. Study included 30 patients with clinically diagnosed SLE and 30 healthy controls (American college of Rheumatology, 1997). SLE was diagnosed according to criteria issued in 1997 by the American College of Rheumatology (ACR). The aim of this study was to evaluate concentration values of each antigen of ENA-6 profile in SLE, to investigate possible correlation between the concentration of Sm antibodies and CIC, and to test their use as possible immunobiological markers in SLE. Furthermore, the aim of our study was to determine whether there is a correlation between Sm antibodies and CIC and SLE activity. The results revealed that all of these ENA-6 and Sm antibodies as biomarkers complement diagnoses of active SLE but their use as solo markers does not allow classifying patients with SLE. Our study has shown that based on calculations from ROC curves, Sm/RNP was clearly a very important marker for diagnosis of SLE (cut off ≥ 9.56 EU, AUC 0,942). The high incidence of Scl-70 (10%) reactivity suggests that ELISA monitoring of this antibody produces more false positive results than other multiplex assay. An important conclusion that can be drawn from the results of our study is that laboratory tests are no more effective than clinical examination for detecting disease relapse, but are helpful in the confirmation of SLE activity.